- Trials with a EudraCT protocol (137)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (8)
137 result(s) found for: Somatostatin.
Displaying page 1 of 7.
EudraCT Number: 2013-002605-65 | Sponsor Protocol Number: DOTA2013/DOTATER | Start Date*: 2013-11-26 |
Sponsor Name:Azienda Ospedaliera di Reggio Emilia Arcispedale S.Maria Nuova/IRCCS | ||
Full Title: Radioreceptor therapy with labeled somatostatin analogues in tumors with high expression of somatostatin receptors. | ||
Medical condition: Patients with tumors expressing somatostatin receptors. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-002338-31 | Sponsor Protocol Number: 47 | Start Date*: 2008-08-29 | |||||||||||
Sponsor Name:Hannover Medical School | |||||||||||||
Full Title: Prospektive randomisierte Phase II Studie zur Behandlung von Patienten mit fortgeschrittenem hormonrefraktären Prostatakarzinom mittels LHRH-Analoga und Somatostatin-Analoga unter Berücksichtigung ... | |||||||||||||
Medical condition: Patients with hormone - independent non metastatic prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-005129-35 | Sponsor Protocol Number: FENET-2016 | Start Date*: 2018-02-22 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA DI FERRARA | |||||||||||||
Full Title: "Peptide Receptor Radionuclide Therapy (PRRT) with somatostatin analogs in tumors over-expressing somatostatin receptors" | |||||||||||||
Medical condition: Tumors over-expressing somatostatin receptors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-008319-24 | Sponsor Protocol Number: AGO/2008/015 | Start Date*: 2009-02-17 | |||||||||||
Sponsor Name:University Hospital Ghent | |||||||||||||
Full Title: A single-center, randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of Somatostatin used as inflow modulator in liver transplantation. | |||||||||||||
Medical condition: Cirrhotic patients receiving a primary liver transplant | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001673-32 | Sponsor Protocol Number: P150915 | Start Date*: 2016-10-19 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: PREVENTION OF POSTOPERATIVE PANCREATIC FISTULA BY SOMATOSTATIN (PREFIPS) | |||||||||||||
Medical condition: Patients candidate for pancreatic surgery (pancreaticoduodenectomy or distal pancreatectomy with or without splenectomy). | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-006889-29 | Sponsor Protocol Number: MEC-2008-322 | Start Date*: 2009-02-25 |
Sponsor Name:ErasmusMC | ||
Full Title: A pilotstudy comparing systemic versus locoregional injection of radiolabelled somatostatin analogues in patients with neuroendocrine Gastro-Entero_Pancreatic (GEP) tumors. | ||
Medical condition: Uptake of Octreoscan in sst-2 receptor positive Gastro Entero Pancreatic neuroendocrine tumors injected in systemical and locoregional way. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002230-20 | Sponsor Protocol Number: CRN00808-03 | Start Date*: 2018-11-13 | |||||||||||
Sponsor Name:Crinetics Pharmaceuticals, Inc. | |||||||||||||
Full Title: An open label exploratory study to evaluate the safety, pharmacokinetics and efficacy of CRN00808 in patients with acromegaly treated with somatostatin analogue based treatment regimens (ACROBAT EDGE) | |||||||||||||
Medical condition: Acromegaly | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) SK (Completed) DE (Completed) GR (Completed) PL (Completed) GB (Completed) IT (Completed) RO (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-006234-16 | Sponsor Protocol Number: INT003 | Start Date*: 2012-03-27 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI | |||||||||||||
Full Title: Evaluation of the efficacy of the tandem treatment [90Y-DOTA, TYR(3)]OCTREOTATE and [177Lu-DOTA, TYR(3)]OCTREOTATE in patients with neuroendocrine tumour expressing somatostatin receptors and refra... | |||||||||||||
Medical condition: Patients bearing neuroendocrine tumour expressing somatostatin receptors refractory to conventional therapies | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002960-42 | Sponsor Protocol Number: Yttrium-90-02 | Start Date*: 2017-11-15 | |||||||||||
Sponsor Name:AZIENDA UNITÀ SANITARIA LOCALE DELLA ROMAGNA | |||||||||||||
Full Title: 173/5000 Forse cercavi: Terapia radiometabolica recettoriale-mediata con [90Y-DOTA0-Tyr3]-octreotide (90Y-DOTATOC) nei tumori endocrini del tratto gastroenteropancreatico e bronchiale. (Yttrium-90... | |||||||||||||
Medical condition: Patients with Somatostatin receptors Neoplasms | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003496-20 | Sponsor Protocol Number: LAR/005 | Start Date*: 2006-10-31 |
Sponsor Name:Oxford Radcliffe Hospitals NHS trust | ||
Full Title: The effect of pre-operative Octreotide LAR treatment on surgical cure rates of subjects with Acromegaly, and post-operative responsiveness to somatostatin analogue treatment in patients not cured s... | ||
Medical condition: Acromegaly, overproduction of growth hormone by (almost always) a benign pituitary tumour. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-005545-20 | Sponsor Protocol Number: IJBNMDOCASTOR | Start Date*: 2014-12-23 | |||||||||||
Sponsor Name:Institut Jules Bordet | |||||||||||||
Full Title: The CaStOR study Carcinoid Tumors after failure of Somatostatin analogs: a randomized phase III of Octreotide Lutate Peptid Receptor radionuclide Therapy (PRRT) versus inteRferon α-2b | |||||||||||||
Medical condition: Progressive, unresectable, non-pancreatic gastrointestinal neuroendocrine tumors resistant to therapy with somatostatin analogues. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001562-15 | Sponsor Protocol Number: CAAA601A22301 | Start Date*: 2019-11-15 | |||||||||||||||||||||
Sponsor Name:Advanced Accelerator Applications SA | |||||||||||||||||||||||
Full Title: This is a multicenter, stratified, randomized, open-label comparator-controlled, Phase III study in patients with somatostatin receptor positive, well-differentiated G2 and G3, advanced GEP NETs, d... | |||||||||||||||||||||||
Medical condition: Patients with somatostatin receptor positive, well-differentiated G2 and G3, advanced GEP NETs | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Ongoing) GB (GB - no longer in EU/EEA) DE (Ongoing) NL (Ongoing) ES (Ongoing) IT (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-000739-25 | Sponsor Protocol Number: CSOM230C2303 | Start Date*: 2008-01-14 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multicenter, randomized, blinded efficacy and safety study of pasireotide LAR vs octreotide LAR in patients with metastatic carcinoid tumors whose disease-related symptoms are inadequately contr... | |||||||||||||
Medical condition: Metastatic carcinoid tumors whose disease-related symptoms are inadequately controlled by somatostatin analogues | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) FR (Completed) DE (Completed) IT (Prematurely Ended) ES (Prematurely Ended) GB (Completed) BE (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004162-41 | Sponsor Protocol Number: C2L-OCT-01 PR-303 | Start Date*: 2007-10-25 | |||||||||||
Sponsor Name:Mallinckrodt Inc. | |||||||||||||
Full Title: SAFETY AND BIOLOGICAL ACTIVITY OF A NEW PROLONGED RELEASE FORMULATION OF OCTREOTIDE ACETATE, C2L-OCT-01 PR, ADMINISTERED INTRA MUSCULARLY EVERY 6 WEEKS IN ACROMEGALIC PATIENTS | |||||||||||||
Medical condition: Acromegaly | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005546-63 | Sponsor Protocol Number: DOTATER1_26_15 | Start Date*: 2016-05-30 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA ARCISPEDALE SANTA MARIA NUOVA/IRCCS DI REGGIO EMILIA | |||||||||||||
Full Title: Peptide receptor radionuclide therapy in tumors with high expression of somatostatine receptors. | |||||||||||||
Medical condition: Cancer patients with high expression of somatostatin receptors (neurendocrine tumors, thyroid tumors, lung tumors, meningiomas). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004231-31 | Sponsor Protocol Number: MEC2011pegvqol | Start Date*: 2013-07-22 |
Sponsor Name:Erasmus University Medical Centre Rotterdam | ||
Full Title: Randomized double blind multi-centre study of the effects on low-dose pegvisomant treatment in acromegalic subjects in whom the IGF1 levels has been normalized by long-acting somatostatin analogues | ||
Medical condition: acromegaly | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2006-004748-22 | Sponsor Protocol Number: ML20058 | Start Date*: 2006-12-14 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA S. LUIGI GONZAGA | |||||||||||||
Full Title: phase II study of the combination of bevacizumab plus somatostatin analogue and metronomic capecitabine as first-line therapy in patients with advanced inoperable well-differentiated neuroendrocri... | |||||||||||||
Medical condition: Patients with Advanced Inoperable Well-Differentiated Neuroendocrine Tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-000492-16 | Sponsor Protocol Number: CCR2739 | Start Date*: 2006-07-20 | |||||||||||
Sponsor Name:Royal Marsden Foundation Hospital | |||||||||||||
Full Title: A Phase II, Single-Centre, Randomised, Controlled, Open-Label Clinical Trial to Compare the Efficacy and Safety of Three Therapeutic Interventions on the Treatment of Hypothalamic Obesity due to Ch... | |||||||||||||
Medical condition: Hypothalamic Obesity due to Childhood Cancer with Cranial Insults | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000549-15 | Sponsor Protocol Number: S63678 | Start Date*: 2020-08-05 |
Sponsor Name:University Hospitals Leuven | ||
Full Title: Al18F-NOTA-octreotide PET imaging of the somatostatin receptor in neuroendocrine tumors | ||
Medical condition: Neuroendocrine tumors | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-004091-35 | Sponsor Protocol Number: EMC-NET1 | Start Date*: 2019-04-19 | |||||||||||||||||||||
Sponsor Name:Erasmus University Medical Center | |||||||||||||||||||||||
Full Title: Improving Treatment Options for Somatostatin Type 2 Receptor Negative Neuroendocrine Tumor Patients | |||||||||||||||||||||||
Medical condition: Neuroendocrine tumors | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.